Related Experiment Video
Updated: Sep 3, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Discovery of LAS194046: A Potent and Selective pan-Janus Kinase (JAK) Inhibitor with a Suitable Profile for Inhaled
Jordi Bach1, Daniel Pérez1, Cristina Esteve1
1Almirall R&D , Laureà Miró 408-410, Sant Feliu de Llobregat, 08980Barcelona, Spain.
Abstract:
Relevant cytokines involved in inflammatory processes in asthma and Chronic Obstructive Pulmonary Disease (COPD) signal through the Janus kinase (JAK) proteins. Therefore, a JAK inhibitor blocking multiple cytokine signaling pathways constitutes a potential new anti-inflammatory therapy for these diseases. Herein is described the discovery and progression of a novel series of pyrazolo[1,5-a]pyridine JAK inhibitors with a profile suitable for inhaled administration. Structural biology-guided design was used to improve potency, kinase selectivity, and lung retention of initial compounds, leading to the identification of compound 18 (LAS194046), a potent and selective pan-JAK inhibitor with an excellent profile for inhaled administration and proven efficacy in the ovalbumin (OVA)-induced airway inflammation model in rat by the inhaled route. As part of the optimization process leading to 18, the relevance of several physicochemical properties in lung retention has also been analyzed.
Related Concept Videos
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Inhaled Medications
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
The JAK-STAT Signaling Pathway
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
